XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenues $ 53,473 $ 54,287 $ 157,283 $ 163,489
Consumables [Member] | Transferred at Point in Time [Member]        
Revenues 31,209 29,329 88,365 89,574
Hardware and Software [Member] | Transferred at Point in Time [Member]        
Revenues 12,745 16,333 39,975 45,320
Service [Member] | Transferred at Point in Time [Member]        
Revenues 9,519 8,625 28,943 28,595
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenues [1] 19,338 [2] 16,283 52,345 [2] 48,021
Operating Segments [Member] | Clinical Genomics [Member]        
Revenues [1] 12,546 15,585 41,464 48,525
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenues [1] 9,430 11,646 28,526 34,757
Operating Segments [Member] | Calibration Solutions [Member]        
Revenues [1] 12,159 10,773 34,948 32,186
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 16,832 [2] 14,307 45,288 [2] 41,239
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 9,758 10,885 28,490 34,815
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 4,080 3,584 12,753 11,248
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues 539 553 1,834 2,272
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 180 [2] 95 381 [2] 619
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 1,639 3,371 9,540 9,349
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 2,672 5,844 7,838 16,656
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues 8,254 7,023 22,216 18,696
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 2,326 [2] 1,881 6,676 [2] 6,163
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 1,149 1,329 3,434 4,361
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 2,678 2,218 7,935 6,853
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues $ 3,366 $ 3,197 $ 10,898 $ 11,218
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues from GKE GmbH and SAL GmbH are included in the Sterilization and Disinfection Control division beginning upon acquisition on October 16, 2023.